Canada Markets closed

Amgen Inc. (AMGN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
248.35-3.74 (-1.48%)
At close: 04:00PM EDT
247.57 -0.78 (-0.31%)
After hours: 05:24PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close252.09
Bid247.55 x 1200
Ask250.00 x 1000
Day's Range247.99 - 253.35
52 Week Range198.64 - 258.45
Avg. Volume3,030,009
Market Cap139.887B
Beta (5Y Monthly)0.58
PE Ratio (TTM)25.60
EPS (TTM)9.70
Earnings DateApr 25, 2022 - Apr 29, 2022
Forward Dividend & Yield7.76 (3.14%)
Ex-Dividend DateMay 16, 2022
1y Target Est251.76
  • Reuters

    Senate Finance Committee looks at Amgen taxes, widening drugmaker probe

    The U.S. Senate Finance Committee is widening its investigation into the tax practices of U.S. drugmakers to include Amgen Inc, according to a letter sent on Thursday by the committee's chairman, Senator Ron Wyden. Amgen is already in the crosshairs of the U.S. Internal Revenue Service over its tax practices, particularly how it allocates profits between the U.S. and Puerto Rico. The IRS is after more than $10 billion in back taxes and penalties the California-based biotech firm, although Amgen has said it believes the proposed adjustments and penalties are without merit.

  • Zacks

    Biotech Stock Roundup: AMGN's Q2 Earnings, CCXI Acquisition & More Updates

    Earnings updates from Amgen (AMGN) and its ChemoCentryx (CCXI) acquisition are a few key highlights from the biotech sector during the past week.

  • Reuters

    Amgen says Lumakras plus immunotherapy for lung cancer needs further study

    A small study of Amgen Inc's Lumakras drug combined with immunotherapy found it helped 29% of advanced lung cancer patients, but liver toxicity was high and further study is needed, the company said ahead of the data presentation on Sunday at the World Conference on Lung Cancer in Vienna. Nearly all of the 58 trial patients treated with the highest dose of genetic-mutation targeting Lumakras experienced elevated liver enzyme levels, and about 20% given the lowest dose saw significant liver toxicity, researchers said.